Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 19/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401032 | 0.96 | MMP13 (0.67) | MMP13GAAMAPTMMP2MMP3 | |
| SCHEMBL6326071 | 0.86 | MMP13 (0.66) | MMP13GAAMAPTMMP2MMP3 | |
| SCHEMBL6326022 | 0.86 | MMP13 (0.69) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6326007 | 0.85 | MMP13 (0.67) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6326829 | 0.83 | MMP13 (0.55) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6323571 | 0.83 | MMP13 (0.66) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6332946 | 0.82 | MMP13 (0.67) | MMP13GAAMAPTMMP2MMP3 | |
| SCHEMBL6331916 | 0.81 | MMP13 (0.76) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6333972 | 0.81 | MMP13 (0.90) | MMP13 | |
| SCHEMBL6330437 | 0.79 | MMP13 (0.47) | MMP13GAAMAPTMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159413-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | NOE MARK C (US) | 2005-07-21 | — | — | US | disclosed |
| US-6841671-B2 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1332146-A2 | SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096803-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2002034753-A2 | SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096803-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP2 | MMP13 39/4885GAA 629/4885MAPT 4203/4885 |
| US-20050159413-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP8 | MMP13 34/4885GAA 511/4885MAPT 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.